Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOX66 + Doxorubicin in Soft Tissue Sarcoma
NCT05100628Phase 1Terminated
- Sponsor
- Noxopharm Limited
- Start
- Feb 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idronoxil in soft tissue sarcoma (STS) (4 cohorts), sponsored by Noxopharm Limited. Primary endpoints: Dose-limiting Toxicities and Adverse Events up to 14 months. Started Feb 2022; status: terminated.
02
Drugs
idronoxil
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05100628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100628.